News

The second international Life Sciences Baltics 2014 forum to be held in Vilnius on September 10-12 will be aimed at enhancing an international cooperation between business and science in the higher value-added life sciences sector.

At this forum, the world-famous representatives of the sector’s academic institutions and business enterprises will share their ideas about regenerative medicine, clinical studies, commercialisation as well as investment attraction. At the forum insights and experience in the field will be shared by representatives of Pfizer, General Electric Healthcare Sciences, the Japanese Science and Technology Agency, the European Federation of Pharmaceutical Industries and Associations (EFPIA), Israel’s Weizmann Institute, and other institutions and companies of this viable sector.  

Life Sciences Baltics 2014 is the biggest international biotechnology, pharmaceutical, medical devices and equipment forum in the Baltic States which brings together life sciences experts from more than 30 countries. By encouraging the exchange of ideas, partnership and progress, the event gives an opportunity for Baltic scientists and entrepreneurs to share ideas, present their achievements, and get acquainted with the latest life sciences developments. Lithuanian Prime Minister Algirdas Butkevičius, who is the official patron of Life Sciences Baltics 2014, says the forum is a great opportunity to present the potential of the Baltic life sciences sector. “The forum is a meeting place for top tier managers and scientists from sector’s leading countries – the USA, Israel, Switzerland, Japan and Germany. I am happy that the Baltic scientists and entrepreneurs engaged in the life sciences sector are valued as desirable partners in the implementation of international programmes and projects such as FP7, Horizon 2020. Lithuanians have gained a reputation as reliable providers of quality scientific research and services in the field of life sciences. This is highly important as trustworthiness is the key element of this sector, giving companies a competitive advantage,” pointed out Prime Minister Algirdas Butkevičius.

Mantas Nocius, director general of Enterprise Lithuania, a company which organises Life Sciences Baltics 2014, supports the Prime Minister’s view about the forum’s importance for Lithuania and other Baltic States. According to Nocius, the first Life Sciences Baltics forum held in September 2012 attracted over 800 participants, a third of whom were from foreign countries such as Israel, the USA, EU member states, etc. The representatives of international companies and institutions such as Baxter, The University of Huston (USA), Merck KGAA (Germany), Genzyme (Israel) and others were among the forum's guests. “The event sheds light on the latest developments in the world. The forum involves an international exhibition, business-to-business (B2B) meetings, visits to companies and universities, startup and student sessions. It is a great opportunity to find new clients and partners for the development of scientific research. This is especially vital given that the life sciences industry is very dynamic and if companies wish to maintain their competitive edge they must regularly increase the awareness of their brand, their products and services,” stated Nocius, highlighting the advantages of the forum.   

Find more information about the event at www.lsb2014.com.